EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Association of high mortality with extended-spectrum β-lactamase (ESBL) positive cultures in community acquired infections



Association of high mortality with extended-spectrum β-lactamase (ESBL) positive cultures in community acquired infections



Journal of Critical Care 44: 255-260



Label="PURPOSE">Infections due to multidrug resistant organisms have become a serious health concern worldwide. The present study was conducted to investigate the spectrum of microbial resistance pattern in the community and their effects on mortality.Label="METHODS">A retrospective review and analysis of prospectively collected data was done of all patients admitted with diagnosis of sepsis in two tertiary care ICU's for a period of two years. Demographics, culture positivity, microbial spectrum, resistance pattern and outcome data were collected.Label="RESULTS">Out of 5309 patients enrolled; 3822 had suspected clinical infection on admission with 1452 patients growing positive microbial cultures. Among these, 201 bacterial strains were isolated from patients who had community acquired infections. 73% were Gram negative bacilli, commonest being E. coli (63%). 63.4% E. coli and 60.7% Klebsiella isolates were ESBL producers. The mortality in ESBL positive infections was significantly higher as compared to ESBL negative infections (Odds ratio 2.756). Moreover, ESBL positive patients empirically treated with Beta Lactams+Beta Lactamase inhibitors (BL+BLI) had significantly higher mortality as compared to patients treated with carbapenems. More data from multiple centres need to be gathered to formulate appropriate antibiotic policy for critically ill patients admitted from the community.

(PDF emailed within 0-6 h: $19.90)

Accession: 051026174

Download citation: RISBibTeXText

PMID: 29220754

DOI: 10.1016/j.jcrc.2017.10.036



Related references

Molecular epidemiology of extended-spectrum beta-lactamase (ESBL)-positive Klebsiella pneumoniae from bloodstream infections and risk factors for mortality. Journal of Infection and ChemoTherapy 20(12): 817-819, 2015

Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. an exploratory case-control study. Plos One 8(9): E74323-E74323, 2014

Clinical and economic outcomes associated with community-acquired intra-abdominal infections caused by extended spectrum beta-lactamase (ESBL) producing bacteria in China. Current Medical Research and Opinion 26(6): 1443-1449, 2010

Prevalence of extended-spectrum β-lactamase-producing multidrug-resistant Escherichia coli among isolates from community-acquired infections and in silico structural modeling of an ESBL protein. Microbial Drug Resistance 20(2): 170-176, 2014

Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum β-lactamase (ESBL) and non-ESBL producing Escherichia coli. Journal of Microbiology, Immunology, and Infection 43(3): 240-248, 2011

Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum beta-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. Bmc Infectious Diseases 6(): 24-24, 2006

Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections. Journal of Infection 54(5): 463-468, 2006

PO-0273Community-acquired Urinary Tract Infections (uti) With Extended-spectrum Beta-lactamase (esbl) Bacteria In A French Paediatric Emergency Department (ped). Archives of Disease in Childhood 99(Suppl 2): A334.2-A334, 2014

In vitro Resistance of extended-spectrum (ESBL) versus AmpC-phenotype (AmpC) beta-lactamase-producing Escherichia coli urinary isolates against six first-line oral antibiotics commonly used for community-acquired urinary-tract infections. 2005

Evaluation of the β-Lacta Test for Detection of Extended-Spectrum-β-Lactamase (ESBL)-Producing Organisms Directly from Positive Blood Cultures by Use of Smudge Plates. Journal of Clinical Microbiology 55(12): 3560-3562, 2017

Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial ChemoTherapy 72(3): 906-913, 2017

Is hand-rub consumption correlated with hand hygiene and rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE)-acquired infections?. Journal of Hospital Infection 80(4): 348-350, 2012

Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: a case-control study. International Journal of Infectious Diseases 55: 16-19, 2016

Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes. Infection Control and Hospital Epidemiology 29(11): 1026-1034, 2008

Worrisome high frequency of extended-spectrum beta-lactamase-producing Escherichia coli in community-acquired urinary tract infections: A case-control study; methodological issues. International Journal of Infectious Diseases, 2017